Latest updates on cellular and molecular biomarkers of gliomas.

Autor:	Bou Zerdan M; Department of Internal Medicine, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States., Atoui A; Hematology-Oncology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon., Hijazi A; Hematology-Oncology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon., Basbous L; Hematology-Oncology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon., Abou Zeidane R; Hematology-Oncology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon., Alame SM; Department of Pediatrics, Faculty of Medicine, Lebanese University, Beirut, Lebanon., Assi HI; Hematology-Oncology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Nov 08; Vol. 12, pp. 1030366. Date of Electronic Publication: 2022 Nov 08 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.1030366
Abstrakt:	Gliomas are the most common central nervous system malignancies, compromising almost 80% of all brain tumors and is associated with significant mortality. The classification of gliomas has shifted from basic histological perspective to one that is based on molecular biomarkers. Treatment of this type of tumors consists currently of surgery, chemotherapy and radiation therapy. During the past years, there was a limited development of effective glioma diagnostics and therapeutics due to multiple factors including the presence of blood-brain barrier and the heterogeneity of this type of tumors. Currently, it is necessary to highlight the advantage of molecular diagnosis of gliomas to develop patient targeted therapies based on multiple oncogenic pathway. In this review, we will evaluate the development of cellular and molecular biomarkers for the diagnosis of gliomas and the impact of these diagnostic tools for better tailored and targeted therapies. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Bou Zerdan, Atoui, Hijazi, Basbous, Abou Zeidane, Alame and Assi.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu